NasdaqGM - Delayed Quote USD

Axsome Therapeutics, Inc. (AXSM)

71.71 +0.19 (+0.27%)
At close: April 26 at 4:00 PM EDT
72.25 +0.54 (+0.75%)
After hours: April 26 at 6:48 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Herriot Tabuteau M.D. Founder, Chairman, CEO & President 1.32M -- 1968
Mr. Hunter Murdock Esq. General Counsel & Secretary 735.39k -- 1980

Axsome Therapeutics, Inc.

One World Trade Center
22nd Floor
New York, NY 10007
United States
212 332 3241 https://www.axsome.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
545

Description

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Corporate Governance

Axsome Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 06, 2024
Axsome Therapeutics, Inc. Earnings Call

Related Tickers

TGTX TG Therapeutics, Inc.
13.47
-3.16%
 
MDGL Madrigal Pharmaceuticals, Inc.
193.33
-0.54%
 
IOVA Iovance Biotherapeutics, Inc.
11.64
+0.87%
 
LXRX Lexicon Pharmaceuticals, Inc.
1.5800
+2.60%
 
ALT Altimmune, Inc.
7.26
+0.83%
 
VKTX Viking Therapeutics, Inc.
74.31
+7.91%
 
AVXL Anavex Life Sciences Corp.
3.4400
+1.47%
 
SAVA Cassava Sciences, Inc.
22.34
+2.81%
 
CYTK Cytokinetics, Incorporated
65.34
+0.83%
 
ANVS Annovis Bio, Inc.
18.01
+32.43%